TLSI vs. INO, UTMD, ANGO, RCEL, SGHT, GUTS, PROF, OBIO, CVRX, and ARAY
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), AngioDynamics (ANGO), AVITA Medical (RCEL), Sight Sciences (SGHT), Fractyl Health (GUTS), Profound Medical (PROF), Orchestra BioMed (OBIO), CVRx (CVRX), and Accuray (ARAY). These companies are all part of the "surgical & medical instruments" industry.
TriSalus Life Sciences (NASDAQ:TLSI) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Inovio Pharmaceuticals received 715 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 71.46% of users gave Inovio Pharmaceuticals an outperform vote.
TriSalus Life Sciences currently has a consensus price target of $16.00, suggesting a potential upside of 62.77%. Inovio Pharmaceuticals has a consensus price target of $96.00, suggesting a potential upside of 801.41%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than TriSalus Life Sciences.
2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
TriSalus Life Sciences has higher revenue and earnings than Inovio Pharmaceuticals.
TriSalus Life Sciences has a net margin of 0.00% compared to Inovio Pharmaceuticals' net margin of -16,238.91%. TriSalus Life Sciences' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.
In the previous week, TriSalus Life Sciences had 4 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 10 mentions for TriSalus Life Sciences and 6 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.84 beat TriSalus Life Sciences' score of 0.64 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
TriSalus Life Sciences has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
Summary
TriSalus Life Sciences and Inovio Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
